Deal Details

Centogene Completes $56 Million Initial Public Offering

Healthcare

Centogene initial public offering

Summary

Centogene B.V. ("Centogene” or the "Company”), (NASDAQ-GS: CNTG) recently completed an initial public offering of 4,000,000 common shares at an offering price of $14.00 per common share, for total gross proceeds of $56 million. In addition, Centogene has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Baird served as a co-manager on this offering.

About

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using its knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. Centogene has developed a global proprietary rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing 115 different countries as of August 31, 2019, or an average of over 500 data points per patient. Centogene is headquartered in Cambridge, Massachusetts and Rostock, Germany.